Clinical trials: Hepatic Steatosis
NAFLD
The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A
In this research, the investigators tested the effect of 12-week supplementation with soy isoflavones on non alcoholic fatty liver disease (NAFLD) management and the level of fibroblast growth factor-21 (FGF-21) and fetuin A as…
- Trial name
- NCT06101433
- Testing
- Soy isoflavone
- Where
- Iran
- Volunteers
- 46 people
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
Nonalcoholic Fatty Liver Disease, Dyslipidemias
Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
To investigate the therapeutic effect of ezetimibe on nonalcoholic fatty liver disease, the effect of rosuvastatin 5mg monotherapy and rosuvastatin 5mg / ezetimibe 10mg combination therapy n patients with hyperlipidemia and fatty…
- Trial name
- NCT03434613
- Testing
- Rosuvastatin, Rosuvastatin/ezetimibe combination
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Yonsei University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLD
This randomized, double-blind, placebo-controlled study evaluated whether Gdue®, a nutraceutical containing extracts of the brown algae Ascophyllum nodosum and Fucus vesiculosus together with chromium picolinate, could improve…
- Trial name
- GDUE (NCT07763626)
- Testing
- Brown Algae and Chromium Picolinate Supplement
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- University of Genova
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Steatohepatitis, Nonalcoholic
The COherence of Scatter Identification and Exclusion Algorithm Study
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040.
- Trial name
- COSIE (NCT06975579)
- Testing
- Ultrasound image processing
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Morbid Obesity, Non Alcoholic Steatohepatitis
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Abstract: Fatty liver most frequently corresponds to a fat overload of the liver. It is usually classified as alcoholic steatosis or non-alcoholic steatosis.
- Trial name
- FIRM (NCT01695083)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Alcoholic Fatty Liver Disease
Aronia and Non-alcoholic Fatty Liver Disease
Adults newly diagnosed with NAFLD will be included in the study. At the beginning of the research, the socio-demographic characteristics and nutritional habits of the individuals will be questioned with a face-to-face…
- Trial name
- NCT06450769
- Testing
- Aronia juice, Mediterranean diet, Low-fat diet
- Volunteers
- 54 people
- Sponsor
- Istanbul Kent University
Cardiac Steatosis, Hepatic Steatosis
Cardiometabolic Effects of Eplerenone in HIV Infection
Background: People with human immunodeficiency virus (HIV) are at a high risk of getting visceral or deep belly fat. Visceral fat can cause health problems like heart or liver disease.
- Trial name
- NCT02629094
- Testing
- Inspra /Eplerenone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 2
Effect of Low-glycemic Index Meals Intake on DM2 Women Under Metformin Therapy
To compare the effect of low-glycemic index versus control lunches and dinners intake on indicators of satiety, metabolic parameters and liver steatosis degree on women with type 2 diabetes under metformin therapy.
- Trial name
- LGIM (NCT03165877)
- Testing
- Low-glycemic index, Control
- Volunteers
- 13 people
- Sponsor
- Universidad de Valparaiso
Non-alcoholic Fatty Liver Disease (NAFLD)
Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)
This study will assess the inter-center reproducibility and accuracy of hepatic fat fraction measurements using up to two MRI-based methods.
- Trial name
- NCT01110577
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Fatty Liver
Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver
fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)
- Trial name
- NCT05623930
- Testing
- laser acupuncture, wet cupping
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
NAFLD (Nonalcoholic Fatty Liver Disease), Hep A
Comparative Effects of Mediterranean and DASH Diet on Hepatic Function
Participants were assigned into three groups Control group recieving general dietary guidelines, Mediterranean diet intervention group DASH dietary intervention group
- Trial name
- NCT07622680
- Testing
- Dietary guidelines for fatty liver, Mediterranean diet, DASH diet
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- University of Lahore
Liver Steatosis, MASH
Acceptability and Feasibility of a New Approach to Engage Patients With Steatotic Liver Disease in Physical Activity
Steatosis is the building of fat in the liver. Steatotic liver disease (SLD) regroups MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) i.e.
- Conditions
- Liver Steatosis, MASH, MASLD
- Trial name
- NCT06446908
- Testing
- Telehealth coaching for liver disease
- Volunteers
- 12 people
- Sponsor
- Hopital Montfort
Hepatic Steatosis, Obesity, Childhood
Attenuation Imaging in Hepatic Steatosis
For obese and normal-weight children, the investigators assess the diagnostic performance of attenuation imaging (ATI) in the detection of hepatic steatosis in children.
- Conditions
- Hepatic Steatosis, Obesity, Childhood, Ultrasonography
- Trial name
- NCT05302258
- Testing
- Attenuation imaging in ultrasonography
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hallym University Kangnam Sacred Heart Hospital
HBV, NASH - Nonalcoholic Steatohepatitis
Mechanism of DCs Dysfunction in Chronic HBV Infection
This research is to better understand the functional impairments of Dendritic cells (DCs) in chronic HBV infection. Aim is to determine if the virus is able to bind to the C-type lectin receptor (CLRs) of DCs to modulate their…
- Trial name
- HepatoDC (NCT03753308)
- Testing
- Blood Sampling, Liver biopsy
- Where
- France
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Steatohepatitis
PET-MR Study of Fatty Liver
This is a pilot, translational study designed to explore the feasibility of molecular imaging with FBA-A20FMDV2, radiolabelled with fluorine-18 ([18F]-FBA-A20FMDV2), in patients with SH and CASH in hepatic metastatic disease.
- Trial name
- iDOSH (NCT04063826)
- Testing
- PET MRI
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Imperial College London
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage…
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
- Trial name
- FALCON 2 (NCT03486912)
- Testing
- BMS-986036
- Where
- 91 sites in United States, Japan
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
NAFLD, Precision Medicine
The Liver BIoBank Lombardia of Fatty Liver
NAFLD is most frequently linked to excess adiposity, insulin resistance and cardiometabolic risk factors, it has become the leading cause of liver disease worldwide, and is associated with increased mortality due to multiple…
- Conditions
- NAFLD, Precision Medicine, Cardiovascular Diseases
- Trial name
- NCT06566105
- Testing
- precision medicine approach
- Where
- Italy
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Human Immunodeficiency Virus, Acquired Immune Deficiency Syndrome Virus
Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis
Human immunodeficiency virus (HIV) infection is a major global health issue with up to 40 million people infected worldwide. Due to highly active antiretroviral therapy, mortality related to acquired immunodeficiency syndrome…
- Conditions
- Human Immunodeficiency Virus, Acquired Immune Deficiency Syndrome Virus, Liver Diseases, Liver Cirrhosis
- Trial name
- Prospec-HIV (NCT02542020)
- Where
- Brazil
- Volunteers
- 2,000 people
- Sponsor
- Oswaldo Cruz Foundation